about
A Becker myotonia patient with compound heterozygosity for CLCN1 mutations and Prinzmetal angina pectoris.Skeletal muscle pathology in Huntington's diseaseThe influence of gender on phenotype and disease progression in patients with Huntington's disease.Update on Huntington's disease: advances in care and emerging therapeutic options.Melatonin and cortisol profiles in patients with pituitary tumors.HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievementsAn impaired metabolism of nucleotides underpins a novel mechanism of cardiac remodeling leading to Huntington's disease related cardiomyopathy.Validation of the first quality-of-life measurement for patients with Huntington's disease: the Huntington Quality of Life Instrument.The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington's disease.
P50
Q34111622-F0602A11-986C-460C-AEB3-EF08D55EE5FAQ34292092-35476E50-A9BC-48C2-9CEC-A000F69F2FF1Q34458645-FB8B8CD9-E0F7-42DB-BDAD-9F2057071DD0Q35540552-ABBE7170-692C-41B7-B509-DFD2922ADFA5Q35558531-B0879C7F-B4CC-4E96-99B7-B2525A517664Q38373328-9A4D69A4-AACF-4990-B7AC-31CBD26ECC55Q38827109-3C7D7D47-67F1-451D-8A0C-C46ED2E87C94Q45288440-12BBA23D-69E4-476D-B82D-E847AE450581Q47554702-08B37CF6-A868-41D8-85A9-2E5BE89538AF
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Daniel Zielonka
@ast
Daniel Zielonka
@en
Daniel Zielonka
@es
Daniel Zielonka
@nl
type
label
Daniel Zielonka
@ast
Daniel Zielonka
@en
Daniel Zielonka
@es
Daniel Zielonka
@nl
prefLabel
Daniel Zielonka
@ast
Daniel Zielonka
@en
Daniel Zielonka
@es
Daniel Zielonka
@nl
P106
P1153
6506851423
P21
P31
P496
0000-0002-4599-5377